Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

What’s Left After Lexicon’s Terminated Partnership With Sanofi

Lexicon Pharmaceuticals Inc.'s (NASDAQ: LXRX) shares made a huge gain on Wednesday after the announcement that its alliance with Sanofi (NASDAQ: SNY) was terminated. The partnership was centered around the ...
Read Full Story »

Is This Lexicon Pharmaceuticals Panic Overblown?

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares were absolutely crushed on Monday after it was announced that Sanofi would be ending its partnership with the firm. This decision comes after Lexicon ...
Read Full Story »

What Lexicon Pharma Could Mean for the Future of Diabetes

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares jumped on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the Marketing Authorization ...
Read Full Story »

Vodafone, Lexicon Pharma Slip Into Friday’s 52-Week Low Club

January 25, 2019: Here are four stocks trading with heavy volume among just 14 equities that have posted new 52-week lows by the noon hour Friday. On the New York ...
Read Full Story »

Immunomedics, Nautilus Sink Into Friday’s 52-Week Low Club

January 18, 2019: Here are four stocks trading with heavy volume among 20 equities that have posted new 52-week lows by the noon hour Friday. On the New York Stock ...
Read Full Story »

FDA Diabetes Treatment Vote to Determine the Fate of Lexicon Therapeutics?

Lexicon Pharmaceutics Inc. (NASDAQ: LXRX) shares fell on Friday after the U.S. Food and Drug Administration (FDA) voted to approve the firm’s type 1 diabetes treatment. Although the result from ...
Read Full Story »

Biopharma Companies to Watch This Week

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with ...
Read Full Story »

Biopharma Companies to Watch This Week and for the Rest of June

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AEP, American Water, BHP Billiton, Boeing, Costco, Crocs, Dollar General, McDonald’s, Ulta Beauty and More

Stocks have been volatile lately, and this Monday was looking to be a positive day despite the geopolitical uncertainty after bombing targets in Syria. The bull market may now be ...
Read Full Story »

Wedbush Makes Big Changes to Best Ideas List for October

With the third-quarter earnings reports ready to start rolling out fast and furious, many of the top analysts we follow on Wall Street are making some changes to the lists ...
Read Full Story »

Equifax, New York REIT Dive into Thursday’s 52-Week Low Club

September 14, 2017: Here are four stocks trading with heavy volume among 24 equities making new 52-week lows in Thursday's session. On the NYSE, advancers led decliners by about 15 ...
Read Full Story »

Equifax, HP Enterprise Tumble into Wednesday’s 52-Week Low Club

September 13, 2017: Here are four stocks trading with heavy volume among 26 equities making new 52-week lows in Wednesday's session. On the NYSE, advancers led decliners by about 8 ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna, Lexicon Pharma and Many More

Stocks were indicated to open slightly lower on Monday after some of the top momentum and crowded technology companies took it on the chin on Friday. Still, a rotation took ...
Read Full Story »

Lexicon Pharmaceuticals Rises on Late-Stage Diabetes Trial

Shares of Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) saw a hand gain early on Friday after the company reported top-line results from its late-stage trial in type-1 diabetes. Specifically, Lexicon announced ...
Read Full Story »
graph

Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential

Needless to say, the biotech world has had a very difficult 18 months. Even the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, have ...
Read Full Story »